{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:29:44Z","timestamp":1786346984997,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13300-026-01892-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:09:10Z","timestamp":1782205750000},"page":"1159-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Basal Insulin Adherence in Patients with Type\u00a02 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact"],"prefix":"10.1007","volume":"17","author":[{"given":"D\u00eddac","family":"Mauricio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4119-7919","authenticated-orcid":false,"given":"Maria","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"P\u00e9rez-S\u00e1daba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1892_CR1","unstructured":"International Diabetes Federation (IDF). IDF Diabetes Atlas 2021. https:\/\/diabetesatlas.org\/. Accessed Sept 2024."},{"key":"1892_CR2","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"DA American","year":"2013","unstructured":"American DA. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;37:S81\u201390.","journal-title":"Diabetes Care"},{"key":"1892_CR3","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1055\/a-1018-9106","volume":"127","author":"R Landgraf","year":"2019","unstructured":"Landgraf R, Aberle J, Birkenfeld AL, et al. Therapy of type\u00a02 diabetes. Exp Clin Endocrinol Diabetes. 2019;127:S73\u201392.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1892_CR4","doi-asserted-by":"crossref","unstructured":"Soriguer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabetes Study. Diabetologia. 2012;55(1):88\u201393.","DOI":"10.1007\/s00125-011-2336-9"},{"issue":"1","key":"1892_CR5","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1038\/s41598-020-59643-7","volume":"10","author":"G Rojo-Martinez","year":"2020","unstructured":"Rojo-Martinez G, Valdes S, Soriguer F, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort diabetes study. Sci Rep. 2020;10(1):2765.","journal-title":"Sci Rep"},{"issue":"6","key":"1892_CR6","first-page":"182","volume":"29","author":"C Crespo","year":"2013","unstructured":"Crespo C, Brosa M, Soria-Juan A, Lopez-Alba A, L\u00f3pez-Mart\u00ednez N, Soria B. Costes directos de la diabetes mellitus y de sus complicaciones en Espa\u00f1a (Estudio SECCAID: Spain estimated cost Ciberdem-Cabimer in Diabetes). Adv Diabetol. 2013;29(6):182\u20139.","journal-title":"Adv Diabetol"},{"key":"1892_CR7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0213-9111(02)71973-0","volume":"16","author":"M Mata-Cases","year":"2001","unstructured":"Mata-Cases M, Anto\u00f1anzas F, Tafalla M, Sanz P. The cost of type\u00a02 diabetes in Spain: the CODE-2 study. Gac Sanit. 2001;16:511\u201320.","journal-title":"Gac Sanit"},{"issue":"8","key":"1892_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10198-015-0742-5","volume":"17","author":"M Mata-Cases","year":"2016","unstructured":"Mata-Cases M, Casajuana M, Franch-Nadal J, et al. Direct medical costs attributable to type\u00a02 diabetes mellitus: a population-based study in Catalonia. Spain Eur J Health Econ. 2016;17(8):1001\u201310.","journal-title":"Spain Eur J Health Econ"},{"key":"1892_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1744-8603-9-17","volume":"9","author":"J Lopez-Bastida","year":"2013","unstructured":"Lopez-Bastida J, Boronat M, Oliva Moreno J, Schurer W. Costs, outcomes and challenges for diabetes care in Spain. Glob Health. 2013;9:17.","journal-title":"Glob Health"},{"key":"1892_CR10","unstructured":"Global Burden of Disease Compare 2021. https:\/\/vizhub.healthdata.org\/gbd-compare\/. Accessed Oct 2024."},{"issue":"4","key":"1892_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.endonu.2013.11.005","volume":"61","author":"F Arrieta","year":"2014","unstructured":"Arrieta F, Rubio-Terr\u00e9s C, Rubio-Rodr\u00edguez D, et al. Estimaci\u00f3n del impacto econ\u00f3mico y sanitario de las complicaciones de la diabetes mellitus tipo 2 en la Comunidad de Madrid. Endocrinol Nutr. 2014;61(4):193\u2013201.","journal-title":"Endocrinol Nutr"},{"key":"1892_CR12","doi-asserted-by":"crossref","unstructured":"Dal Canto E, Ceriello A, Ryden L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25\u201332.","DOI":"10.1177\/2047487319878371"},{"key":"1892_CR13","unstructured":"Alem\u00e1n JJ, Artola S, \u00c1vila L, et al. Gu\u00eda de diabetes tipo 2 para cl\u00ednicos: recomendaciones de la redGDPS 2018. https:\/\/www.redgdps.org\/gestor\/upload\/colecciones\/Guia%20DM2_web.pdf. Accessed Aug 2024."},{"issue":"2","key":"1892_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13300-019-0590-x","volume":"10","author":"B Guerci","year":"2019","unstructured":"Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type\u00a02 diabetes. Diabetes Ther. 2019;10(2):437\u201349.","journal-title":"Diabetes Ther"},{"issue":"11","key":"1892_CR15","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/dc16-1925","volume":"40","author":"K Khunti","year":"2017","unstructured":"Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type\u00a02 diabetes: a meta-analysis. Diabetes Care. 2017;40(11):1588\u201396.","journal-title":"Diabetes Care"},{"issue":"9","key":"1892_CR16","first-page":"1081","volume":"26","author":"EL Eby","year":"2020","unstructured":"Eby EL, Bajpai S, Faries DE, Haynes VS, Lage MJ. The association between adherence to insulin therapy and health care costs for adults with type\u00a02 diabetes: evidence from a U.S. retrospective claims database. J Manag Care Spec Pharm. 2020;26(9):1081\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"1892_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.endinu.2017.08.004","volume":"64","author":"E Garc\u00eda D\u00edaz","year":"2017","unstructured":"Garc\u00eda D\u00edaz E, Ram\u00edrez Medina D, Garc\u00eda L\u00f3pez A, Morera Porras OM. Determinants of adherence to hypoglycemic agents and medical visits in patients with type\u00a02 diabetes mellitus. Endocrinol Diabetes Nutr. 2017;64(10):531\u20138.","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"12","key":"1892_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s12325-015-0266-5","volume":"32","author":"SL Slabaugh","year":"2015","unstructured":"Slabaugh SL, Bouchard JR, Li Y, Baltz JC, Meah YA, Moretz DC. Characteristics relating to adherence and persistence to basal insulin regimens among elderly insulin-na\u00efVe patients with type\u00a02 diabetes: pre-filled pens versus vials\/syringes. Adv Ther. 2015;32(12):1206\u201321.","journal-title":"Adv Ther"},{"key":"1892_CR19","unstructured":"THIN. The Health Improvement Network. https:\/\/www.the-health-improvement-network.com\/es\/. Accessed Aug 2024."},{"issue":"12","key":"1892_CR20","doi-asserted-by":"publisher","first-page":"S518","DOI":"10.1016\/j.jval.2023.09.2793","volume":"26","author":"A Valente","year":"2023","unstructured":"Valente A, Morros M, Art\u00e9s M, Iglesias C. RWD76 assessing the external validity of thin database in Spain: a reliable source of real-world data for observational retrospective research. Value Health. 2023;26(12):S518.","journal-title":"Value Health"},{"key":"1892_CR21","unstructured":"MInisterio de Sanidad. Portal estad\u00edstico. Conjunto M\u00ednimo B\u00e1sico de Datos desde 2016 en adelante. https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S\/rae-cmbd. Accessed 2024."},{"key":"1892_CR22","unstructured":"Gisbert, R y Brosa, M. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud. Barcelona: Oblikue Consulting, S.L; 2007. http:\/\/www.oblikue.com\/bddcostes\/. Accessed 2024."},{"key":"1892_CR23","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Encuesta de estructura salarial. https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177025&menu=ultiDatos&idp=1254735976596. Accessed 2024."},{"issue":"5","key":"1892_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s13300-024-01559-w","volume":"15","author":"EJ Gimeno","year":"2024","unstructured":"Gimeno EJ, Bogelund M, Larsen S, et al. Adherence and persistence to basal insulin among people with type\u00a02 diabetes in Europe: a systematic literature review and meta-analysis. Diabetes Ther. 2024;15(5):1047\u201367.","journal-title":"Diabetes Ther"},{"key":"1892_CR25","doi-asserted-by":"crossref","unstructured":"Aroda VR, Nielsen N, Mangla KK, et al. Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type\u00a02 diabetes: a retrospective database analysis. BMJ Open Diabetes Res Care. 2024;12(2):e003825.","DOI":"10.1136\/bmjdrc-2023-003825"},{"key":"1892_CR26","doi-asserted-by":"crossref","unstructured":"An J, Nichols GA, Qian L, et al. Prevalence and incidence of microvascular and macrovascular complications over 15\u00a0years among patients with incident type\u00a02 diabetes. BMJ Open Diabetes Res Care. 2021;9(1):e001847.","DOI":"10.1136\/bmjdrc-2020-001847"},{"issue":"10","key":"1892_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.endonu.2016.08.003","volume":"63","author":"R Nu\u00f1o-Solin\u00eds","year":"2016","unstructured":"Nu\u00f1o-Solin\u00eds R, Alonso-Mor\u00e1n E, Arteagoitia Axpe JM, Ezkurra Loiola P, Orueta JF, Gaztambide S. Healthcare costs of people with type\u00a02 diabetes mellitus in the Basque Country (Spain). Endocrinol Nutr. 2016;63(10):543\u201350.","journal-title":"Endocrinol Nutr"},{"issue":"1","key":"1892_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12933-021-01414-3","volume":"20","author":"E Longato","year":"2021","unstructured":"Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type\u00a02 diabetes: a region-wide retrospective study. Cardiovasc Diabetol. 2021;20(1):222.","journal-title":"Cardiovasc Diabetol"},{"key":"1892_CR29","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.2147\/PPA.S107543","volume":"10","author":"KS Boye","year":"2016","unstructured":"Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type\u00a02 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence. 2016;10:1573\u201381.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1892_CR30","first-page":"589","volume":"16","author":"TB Gibson","year":"2010","unstructured":"Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16(8):589\u2013600.","journal-title":"Am J Manag Care"},{"issue":"3","key":"1892_CR31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-018-0421-5","volume":"9","author":"M Perez-Nieves","year":"2018","unstructured":"Perez-Nieves M, Boye KS, Kiljanski J, Cao D, Lage MJ. Adherence to basal insulin therapy among people with type\u00a02 diabetes: a retrospective cohort study of costs and patient outcomes. Diabetes Ther. 2018;9(3):1099\u2013111.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1892_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s10198-006-0367-9","volume":"7","author":"M Ballesta","year":"2006","unstructured":"Ballesta M, Carral F, Olveira G, Giron JA, Aguilar M. Economic cost associated with type\u00a0II diabetes in Spanish patients. Eur J Health Econ. 2006;7(4):270\u20135.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1892_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1345\/aph.1K671","volume":"43","author":"BC Martin","year":"2009","unstructured":"Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36\u201344.","journal-title":"Ann Pharmacother"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01892-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01892-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:00:45Z","timestamp":1786345245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01892-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1892"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01892-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D\u00eddac Mauricio has provided advisory services in the project. Virginia Pascual is an employee of Novo Nordisk. Maria Soler and Francisco J P\u00e9rez-S\u00e1daba work for an independent research entity and have received fees for their contribution to project development and medical writing.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and it was evaluated and approved by the Clinical Research Ethics Committee at Hospital Cl\u00ednic de Barcelona (approval reference number HCB\/2023\/1115). Because of the retrospective design of the study and that THIN\u00ae is an anonymized database where patients cannot be identified, the Clinical Research Ethics Committee approved the waiver of informed consent. This study used anonymised, project\u2011specific data extracts from the THIN\u00ae database, with permission from the database owner. The authors did not have access to the underlying source database.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}